Our Science

Adiso is a clinical stage company advancing an innovative pipeline of multimodal, locally acting small molecules aimed at modulating inflammation precisely at the site of insult.

We focus on chronic and progressive inflammatory diseases with a high unmet need for targeted therapies

Dysregulated inflammation is central to many serious diseases and current treatment paradigms are inadequate to stop disease progression. We see a significant opportunity to serve patients and the overall marketplace with our highly differentiated and locally acting therapies across a wide range of inflammatory diseases.

Multimodal activity contributes to efficacy while local targeting diminishes risk of off-target effects including immunosuppression
ADISO DEVELOPMENT PORTFOLIO

First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FRP1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.

Portfolio of First-In-Class Small Molecule Inhibitors of the NLRP3 and 1 Inflammasomes

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases. Our development candidates are focused on Respiratory and Dermal inflammation.

ADISO PARTNERING PORTFOLIO

Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 CDI

Prevention of CDI Recurrence

ADS024 is an orally dosed, naturally occurring single strain live biotherapeutic product (SS-LBP) and in CDI has a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. Difficile while maintaining gut homeostasis. ADS024 is manufactured from a pure clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from human donor fecal material.

ADS024 UC

Ulcerative Colitis

ADS024 is an orally dosed, naturally occurring single strain live biotherapeutic product (SS-LBP) with multi modal mechanisms of actions. The bacteria can modulate inflammation and simultaneously protect the gut barrier. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug, eliminating the need to directly source from human donor fecal material.

ADS012

Neuroinflammation

ADS012 has demonstrated pre-clinical efficacy in 7 models of neuroinflammatory disease at 5 different CRO’s. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis